These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 18940948
1. The risk of asthma mortality with inhaled long acting beta-agonists. Wijesinghe M, Perrin K, Harwood M, Weatherall M, Beasley R. Postgrad Med J; 2008 Sep; 84(995):467-72. PubMed ID: 18940948 [Abstract] [Full Text] [Related]
2. Safe use of long-acting β-agonists: what have we learnt? Sears MR. Expert Opin Drug Saf; 2011 Sep; 10(5):767-78. PubMed ID: 21521133 [Abstract] [Full Text] [Related]
3. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Tamm M, Richards DH, Beghé B, Fabbri L. Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165 [Abstract] [Full Text] [Related]
4. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Sears MR, Ottosson A, Radner F, Suissa S. Eur Respir J; 2009 Jan; 33(1):21-32. PubMed ID: 18768573 [Abstract] [Full Text] [Related]
5. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. Prenner BM. Curr Opin Pulm Med; 2008 Jan; 14(1):57-63. PubMed ID: 18043276 [Abstract] [Full Text] [Related]
6. Overall asthma control: the relationship between current control and future risk. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, Jenkins C, Humbert M, Buhl R, Harrison TW, Quirce S, O'Byrne PM. J Allergy Clin Immunol; 2010 Mar; 125(3):600-8, 608.e1-608.e6. PubMed ID: 20153029 [Abstract] [Full Text] [Related]
7. Is it safe to use long-acting beta-agonists in asthma and chronic obstructive pulmonary disease? Implications of recent trials and meta-analyses. Sears MR. Pol Arch Med Wewn; 2008 Dec; 118(12):761-6. PubMed ID: 19202956 [Abstract] [Full Text] [Related]
8. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. Eltonsy S, Forget A, Beauchesne MF, Blais L. J Allergy Clin Immunol; 2015 Jan; 135(1):123-30. PubMed ID: 25226849 [Abstract] [Full Text] [Related]
9. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. Ankerst J. J Asthma; 2005 Nov; 42(9):715-24. PubMed ID: 16316864 [Abstract] [Full Text] [Related]
10. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Thorax; 2010 Jan; 65(1):39-43. PubMed ID: 20029037 [Abstract] [Full Text] [Related]
11. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Cave AC, Hurst MM. Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815 [Abstract] [Full Text] [Related]
12. Long-acting β-agonists in asthma management: what is the current status? Mysore S, Ruffin RE. Drugs; 2011 Nov 12; 71(16):2091-7. PubMed ID: 22035511 [Abstract] [Full Text] [Related]
13. Long-acting inhaled beta(2)-agonist therapy in asthma. Kips JC, Pauwels RA. Am J Respir Crit Care Med; 2001 Sep 15; 164(6):923-32. PubMed ID: 11587972 [No Abstract] [Full Text] [Related]
14. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease. Cyr MC, Beauchesne MF, Lemière C, Aaron SD, Blais L. Ann Pharmacother; 2010 Apr 15; 44(4):613-22. PubMed ID: 20233915 [Abstract] [Full Text] [Related]
15. [Combined inhaled corticosteroid and long-acting beta-2-agonist in one inhaler in the treatment of chronic obstructive pulmonary disease]. Pedersen ST. Ugeskr Laeger; 2005 Jun 06; 167(23):2504-6. PubMed ID: 16008004 [No Abstract] [Full Text] [Related]
16. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM. Curr Med Res Opin; 2009 Sep 06; 25(9):2251-8. PubMed ID: 19622006 [Abstract] [Full Text] [Related]
17. Dispensation of long-acting β agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. Sadatsafavi M, Lynd LD, Marra CA, FitzGerald JM. Thorax; 2014 Apr 06; 69(4):328-34. PubMed ID: 24281327 [Abstract] [Full Text] [Related]
18. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma. Blanchette CM, Culler SD, Ershoff D, Gutierrez B. Clin Ther; 2009 Nov 06; 31(11):2574-83. PubMed ID: 20110003 [Abstract] [Full Text] [Related]
19. Twenty-five statements on early initiation of fixed combination ICS/LABA treatment for asthma and COPD in primary and secondary care: consensus research by a modified Delphi process. Kardos P, Bechtel B, Palovis L, Hagedorn C, Latif F. Pneumologie; 2012 Sep 06; 66(9):549-57. PubMed ID: 22899206 [Abstract] [Full Text] [Related]
20. Application of multicategory exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink. Ali AK, Hartzema AG, Winterstein AG, Segal R, Lu X, Hendeles L. Value Health; 2015 Mar 06; 18(2):260-70. PubMed ID: 25773561 [Abstract] [Full Text] [Related] Page: [Next] [New Search]